With Eli Lilly's much anticipated solanezumab final phase trial failing (on the same day as this executive appointment), I am going to sit on the side line for a bit on CGS. From the appointment one can see the upcoming investment in a potentially costly project that may or may not return... we shall see.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
0.050(2.79%) |
Mkt cap ! $312.3M | |||
| Open | High | Low | Value | Volume |
| $1.81 | $1.84 | $1.79 | $19.96K | 11.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.84 | 1424 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |